« Back to Research Deepdives

Mendelian Randomisation Says Vitamin E Increases Heart Disease Risk?

This content is restricted to members.

To view our premium content, sign up for a membership:

 

Register New Account

Choose your membership level

Choose Your Payment Method

‹ Back to Research Deepdives

References

1. Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radical Biology and Medicine. 2014;72:76–90.
2. Meydani M. Vitamin E and Atherosclerosis: Beyond Prevention of LDL Oxidation. The Journal of Nutrition. 2001;131(2):366S-368S.
3. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459–72.
4. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2020;1–28.
5. Ohukainen P, Virtanen JK, Ala-Korpela M. Vexed causal inferences in nutritional epidemiology—call for genetic help. International Journal of Epidemiology. 2021;dyab152.
6. Hooper L, Ness AR, Davey-Smith G. Antioxidant strategy for cardiovascular disease. Lancet. 2001;357:1705–6.
7. Lonn E. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. Journal of the American Medical Association. 2005;293(11):1338–47.
8. Mattson MP. Hormesis defined. Ageing Research Reviews. 2008;7(1):1–7.
9. Holst B, Williamson G. Nutrients and phytochemicals: from bioavailability to bioefficacy beyond antioxidants. Current Opinion in Biotechnology. 2008;19(2):73–82.